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Abstract 
Introduction:  Comprehensive musculoskeletal assessment for monitoring joint health 
in haemophilia requires both physical assessment with Haemophilia Joint Health Score 
(HJHS)    and assessment of self-reported function by Haemophilia Activities List (HAL).  
Methods: Correlation between physical assessment and joint function was undertaken 
between HJHS and HAL in patients with SHA and SHB who had both assessments at the 
same visit over a one-year period.  
Results: Data from 120 patients (96-SHA/ 24=SHB) with a median age 33 years (range 
19-73) were included.  Median total HJHS was 19, increasing with age;  18-30 yrs - 7, 
31-50 yrs - 25 and 51-73 yrs- 44. Median total HAL score similarly was 80 with 
decreased function associated with increasing age;  18-30 yrs-90.4, 31-59 yrs - 71.7, 
51-73 yrs -49.5. Median Total HJHS and HAL demonstrated strong correlation (rs= 0.66, 
P<0.01). Moderate to strong correlation was seen across the entire age group between 
the HJHS LL and UL subtotals and corresponding limb HAL domains. Within age groups, 
correlations were less significant particularly for the upper UL domains in HAL and the 
UL HJHS score.  
Conclusion:   HJHS and HAL showed moderate to strong correlation with discrepancy 
in some individual patients. Prospective studies are required to better understand the 
clinical utility of both especially in severe joint disease where HAL may have a 
pototential advantage.  
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Introduction 
 
Modern haemophilia care within a comprehensive care setting ensures persons  with 
severe haemophilia (PWSH) (A and B) are reviewed regularly to ascertain treatment 
effectiveness and for monitoring treatment and disease complications.[1] Although 
regular prophylaxis is the standard of care, recurrent bleeding into joints and muscles 
continues to be seen resulting in sequelae in the musculoskeletal (MSK) system with 
long term morbidity. Further, in developed countries, patients currently over the age 
of 65 had no access to prophylaxis   until adulthood, and those over 45 years had no 
access  to regular prophylaxis  for most of their childhood and the majority of PWSH 
across the world continue to have limited  access to regular prophylaxis.[2] 
Consequently most of these men have established multi joint arthropathy, usually 
affecting 4-6 of the main joints affected by haemophilia – the elbows, knees, ankles [3] 
and  joint disease remains the main cause of morbidity in older persons with 
haemophilia.[4]  
 
Traditionally in haemophilia care, factor VIII and IX trough levels and annualised bleed 
rates have been used to monitor the effectiveness  of replacement therapy and regular 
prophylaxis.[5] There is increasing interest in using assessments that evaluate other 
aspects of a disease process that are personalised, and both patient reported and 
clinician led.[6, 7]  Outcome assessments that evaluate both structure and function of 
the MSK system have been suggested to enhance the care of haemophilia patients.[8]  
The  chosen assessments need to be sensitive to change in the  outcomes of interest 
for monitoring treatment efficacy and tailoring   intervention strategies[9]. Further, it 
is preferable that such measures utilise a framework such as the World Health 
Organisation International Classification of Functioning, disability and health (ICF), that 
evaluates  disease in the domains of body functions and structure, activity, 
participation and environmental context.[10]     
 
A physical assessment typically includes an objective assessment of joint health and 
this can be standardised for monitoring over time and comparisons across centres. 
Such tools include World Federation of Haemophilia (WFH) physical examination score 
(aka Gilbert score) and Haemophilia Joint Health Score (HJHS).[9, 11] Assessments that 
have been developed for measuring activity and functional limitation for persons with 
haemophilia (PWH) include the Functional Independence Score in Haemophilia (FISH) 
and Haemophilia Activities List (HAL).[9, 12, 13] This dual approach is recommended by 
the World Federation of Haemophilia (WFH) in assessing health and disability in PWH.  
 
The HJHS (vers 2.1), is a 9-item assessment tool developed and validated by the 
International Prophylaxis Study Group (IPSG) to identify early signs of joint damage in 
PWH. [14, 15] Its development was based on additions to the Gilbert scale and further 
merging of the Colorado and Stockholm scales.[16]  It has been demonstrated to be 
reliable and sensitive in previous studies [16], although its specificity has not yet been 
determined. The Gilbert score is increasingly not considered to be sensitive for 
mild/moderate damage, resulting in an increasing uptake of the HJHS for surveillance 
both in routine clinical practice and clinical trials, although the tool has not been 
validated in adults over the age of 30 nor for severe joint damage. [2]   
 
The HAL is a haemophilia specific questionnaire evaluating self-perceived functional 
abilities covering daily function of the arms, legs and whole body, and is relatively 
quick and easy for the patient to complete. In adult PWH it has been shown to have 
reasonable reliability in measurement of function, although its sensitivity to measuring 
change over time has yet to be established.[12, 17]  
 
Table 1. HJHS and HAL domain description 
 
Although the WFH recommends the above tools [9] there is considerable uncertainty 
on the application of these tools for assessment of joint damage  given the disparity in 
joint health associated with haemarthropathy in the haemophilia population, or if they 
offer day to day clinical utility. A recent review of practice with physiotherapists across 
the UK highlighted that the vast majority (83%) of those questioned used the HJHS in 
practice (in both paediatric and adult care), but only about 25% use the HAL or 
PedHAL. [18]  
 
As there is limited published evidence on the value of these tools in routine clinical 
practice, the aim of this retrospective review was to evaluate in the first instance the 
relationship between joint health assessed physically and perceived function in our 
patient group. The primary objective was to describe the correlation between the 
HJHS and the HAL across a range of age groups and joint damage in adult patients; and 
the secondary objective was to assess the correlation at the level of limbs and explore 
the potential for using HAL instead of HJHS in patients with widespread joint damage.  
Methods 
A retrospective review of PWSH A and B attending for review clinics for the period 1st 
April 2012-31st March 2013 was undertaken. Adult patients were eligible provided an 
assessment that included both the HJHS and the HAL had been completed at the same 
visit.  Those with previous orthopaedic surgery were included in the dataset. As this 
was a review of existing practice and considered a service development by the NHS 
England research ethics committee, informed consent was not required.  
 
Joint health was measured by the HJHS (vers 2.1), undertaken by an experienced 
haemophilia physiotherapist (PML) with extensive experience in the use of the 
assessment tool and relevant training. The HAL questionnaire was provided to the 
patient to complete on arrival at the clinic. On completion, the raw data for the HAL 
was transferred to an excel spreadsheet designed to calculate the values required for 
its clinical interpretation and use.  
 
A structured form was used to extract information pertaining to the baseline diagnosis 
and major concomitant illnesses including HIV and hepatitis C infection. The HJHS 
subtotals for each individual joint assessed, a combined lower limb (LL) total of both 
ankles and knees, combined upper limb subtotal (both elbows) and the overall total 
(including the gait score) were calculated. The individual domain values for the HAL 
components as well as the overall total, were included for each patient.  
 
Statistics 
Patient characteristics were described using descriptive statistics and Spearman’s 
correlation analysis was completed using SPSS. Analysis included correlations between 
HJHS (total score, UL and LL subtotals) and HAL scores (total score and domain scores) 
by age group. Age was used as a surrogate marker for severity of joint damage. No 
corrections for multiple testing were carried out, since the primary interest was in the 
correlation between the total score of HALS and total joint score of all patients. 
Further correlations were calculated to back up this main analysis, to assess (a) if 
overall correlations held within specific age groups used as surrogate marker for joint 
damage (b) to assess whether correlations were specific to certain areas of the body.  
 
Results 
Patient characteristics   
A total of 335 clinic attendances were available for review between 1st April 2012 and 
31st March 2013. 120 PWSH A (n=96) and B (n=24) >18 years, who had both a HJHS and 
HAL completed at the same visit were eligible for inclusion in the final analysis, 
representing 74% of patients registered at this centre.  
 
Patient characteristics are detailed in Table 2. The cohort median age was 33 years 
(range 19-73). Of the 120 patients, 77.5% (93/120) were receiving regular prophylaxis 
and 22.5% (27/120) were on-demand management. One had an inhibitor to factor VIII, 
and two an inhibitor to IX. Age was used as a surrogate for initiation and intensity of 
prophylaxis and three groups were defined.  Most patients in age group of 18-30 years 
(n=50) have benefited from early onset prophylaxis and in the majority prophylaxis 
was initiated within the first few years of life. Patients in the 31-50 years (n=47) group 
would have been offered secondary prophylaxis in teens or as young adults and 
patients between 51-73 years (n=23) started in adulthood.  
 
Table 2 – Patient Demographics 
Table 3 - HJHS and HAL domain scores by age 
 
Physical joint status (HJHS) 
Summary scores of HJHS by age group are presented in Table 3. The median HJHS 
score for those aged 18-30 years was 7, increasing to 25 in those aged 31-50 yrs, and 
to 44 in those aged 51 yrs and over. The median scores progressively increased with 
increasing age reflecting increasing damage. Importantly the scores confirm previous 
findings that the ankles are the most commonly affected joint in all ages groups.[19] 
The range of movement (ROM)  for patients who scored a maximum 3 (loss of 
>20°ROM) on the HJHS was also evaluated. In the elbow, loss of extension ranged from 
21°to 90° and loss of flexion from 21°to 45°. In the knee, loss of extension ranged from 
22° to 90°, and loss of flexion ranged from 42° to 90° and in the ankle loss of 
plantarflexion ranged from 21° to 40°. Dorsiflexion is not included here as normative 
values for dorsiflexion mean that even with a zero-degree ROM measure may still 
score zero on the HJHS. The wide range of loss of ROM in joints categorised as 
markedly affected highlights the fact that the HJHS has been developed for identifying 
early joint damage and its sensitivity for monitoring progression of joint damage in 
severely affected patients is likely to be limited. [20]  
 
Joint functional status (HAL) 
Within all HAL domains relating to the lower limbs such as LSKS, LEGS, LOWBAS and 
LOWCOM the decrease in perceived function scores were substantially more marked 
in older individuals than those relating to the upper limb such as ARMS, SELFC, 
HOUSEH and UPPER. (Table 3). The largest difference was 60 points in the LOWCOM 
domain between youngest and oldest groups, compared to a difference of only 28 in 
the self-care domain (even with the higher joint scores for elbow in this age group).  
 
Correlations 
The correlation between the joint damage reported using HJHS and function as 
assessed by the patient was explored. Figure 1 demonstrates the overall relationship 
between HJHS and HAL in all patients below and above age 30. Spearman’s Rho 
correlation was estimated to determine the relationship between the components of 
the HAL and the HJHS and presented in Table 4.  
 
Table 4 – Correlation values between HAL domain scores and HJHS domain scores 
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 Overall, there was a highly significant strong negative monotonic correlation between 
the total HJHS score and the total HAL score with increasing joint damage associated 
with poorer function (r=-0.66, p<0.001). Correlations were of comparable magnitude 
when examining the upper and lower limbs independently within HAL domains that 
were more limb specific (such as ARMS for UL), and although less strong in combined 
functional activities such as LEISPO, HOUSEH and SELFC, where the correlations 
remained moderately strong (p=<0.01)  
 
Sub analysis within age groups showed some decrease in strength of correlation from 
the cohort total. In the 18-30 group, the self-care domain and UL score showed no 
significant correlation, whereas all other domains remained significant (p<0.01).  The 
31-50 age group had weaker correlations between the lower limb specific HAL 
domains of LEGS and LOWBAS, as well as overall functional domains of SELFC AND 
LSKS. Interestingly, even with greater joint damage in both the upper and lower limbs, 
the 51-73 year age group showed no significant correlation between total HJHS score 
and household, leisure or sports activity and between total LL HJHS scores and LEGS 
function.  
 
Discussion: 
Musculoskeletal assessment in a cohort of severe  haemophilia A and B patients  
representative of patients across the UK with access to both primary and secondary 
prophylaxis, demonstrates increasingly severe joint damage with increasing age. 
Increasing damage was associated with limitation of functional activities as reported 
by patients.  Our data  reveals a statistically significant,    moderately strong  
correlation between total HJHS and total HAL across a wide age range  and joint 
damage. Our data reiterates the observation that overall the ankle is the most affected 
joint, even in a younger age group with access to early prophylaxis. Importantly the 
strength of correlation did not increase with increasing joint damage and this might be 
related to the lack of sensitivity of either instrument to joint damage or patients’ 
ability to compensate for functional limitations with life style adjustments.    
 
The HJHS median scores in our cohort are comparable to the median scores in a study 
comparing outcomes of an intermediate and high dose prophylactic regime in younger 
adults. [21]. Our cohort with range of treatment had median HJHS of 7 and HAL score 
of 90.35 which are similar to the intermediate dose cohort (n=78) with a median HJHS 
of 9.0, and a HAL of 93. The high dose (n=50) reported a median HJHS of 4.0 and HAL 
of 99, highlighting the very positive effect of early  haemophilia treatment. 
 
The use of HJHS (version 1.0)and HAL in a  younger cohort with limited joint damage 
has been explored in 22 patients (age range 14-30), with lower median HJHS score of 
5.5 (range of 0-34), compared to 7 in our 18-30 cohort (range 0-63) with a weaker 
correlation of -0.40 between the HJHS and HAL total scores compared to a correlation 
of -0.65 in this cohort. [2]. In another  international cross-sectional study of severe 
haemophilia patients on primary prophylaxis since median age of 3.4 years, no 
correlation was identified between total HAL and total HJHS when both objective and 
subjective assessments of joint function were undertaken at a median 25.5 years 
(range 16.0-37.6).[22]  
 
In a study exploring the risk factors for reduced physical activity and functional 
limitations in PWH, although  haemophilic arthropathy was independently associated 
with reduced physical functioning and physical activity, much of the variability was not 
explained by arthropathy.[23]  The authors suggested that other factors including 
motivation, expectation of activity and patient lifestyle might play a more a significant 
role in an individual’s choice to participate, reiterating the need for dual assessment. 
This may help explain the poor correlation between joint disease and leg functions, 
self-care and household domains in the over 50’s cohort analysed here.  
 
In this cohort self-care, leisure and sport and household tasks demonstrated a good 
correlation with the elbow joint score when patients were analysed as single group. 
Suprisingly, no correlation was seen in the 18-30 group suggesting  a lack of functional 
impairment with minimal   joint damage, or a floor effect of the HAL. However, it also 
became less significant in the 51-73 age group, even in the presence of marked joint 
damage.   In this group availability of treatment was markedly limited in their younger 
years resulting in   elbow joint damage being established early. It is conceivable that 
the need to maintain independence in self-care ADLs resulted in an accommodation of 
the occupational limitation of the arthropathy. The lack of strong correlation may also 
be related to psychosocial adjustments (to their physical disability) that PWH undergo 
to cope with their reduced function and the proposed mechanisms used being that of 
a task orientated one.[24, 25]  Other possibilities include the lack of discrimination for 
severity of some aspects of joint damage in the current HJHS scoring system.  The wide 
range of ROM in joints categorised as markedly affected ( i.e. ROM loss score =3) 
highlights the potential ceiling effect of this domain score and its use in chronically 
damaged joints. This may be a weakness in using a tool designed for detection of early 
disease in older adults with well-established joint disease. Further, it does not include 
other joints that can be affected by haemarthropathy (such as the shoulder and hip) –
both of which could affect overall perceived function.  It may also highlight the 
possibility that the HAL is not asking the right questions in relation to function of the 
elbow, and more investigation is warranted of this. 
 
Limitations of this analysis include the use of HJHS which has not been validated in 
adults with joint damage. HJHS was implemented as a pragmatic assessment tool for 
regular musculoskeletal reviews as it allowed the same assessment tool to be used for 
all age groups. Empirically we note that in those with already established joint 
damage, the joint score does not alter significantly from year to year. However, in a 
younger population it has been shown to be sensitive enough to discriminate between 
early and late prophylaxis, as well as inhibitor and non-inhibitor patients. [26]  
 
As the HJHS is used for routine assessments, patients who had previous orthopaedic 
surgery were included in the dataset – as aspects of the HJHS and HAL can change for 
the better when a joint undergoes orthopaedic intervention (e.g. pain, ROM, swelling, 
crepitus), a potential limitation for evaluating the sensitivity and specificity of the 
tools. Further, the HJHS total in some patients can be perceived as artificially low due 
to amputations, joint fusions, or limbs affected by polio for example. Whilst this may 
not capture the degree of actual joint disease secondary to haemophilic arthropathy, it 
may account for an improvement in physical health and perceived function. As a 
consequence, patients who had non evaluable (NE) joints as part of the assessment, 
even though older in age, had lower joint score totals. However, when using this score 
clinically, we are comparing the patient to themselves, and so it accommodates well to 
the individual presentation. This highlights the risk of using the HJHS in isolation and 
why care has to be taken when only looking at the HJHS total as an outcome measure. 
Further, no other measures of quality of life or pain were included for correlation 
purposes.  
Our analysis shows a moderately strong correlation between HJHS and HAL with 
increasing joint damage reflecting how individuals view their function as a result.  The 
HJHS currently does not categorise the joint damage by severity, and importantly, is 
skewed to identifying early damage.  The wide ROM deficits seen in joints with 
maximal scores limits it utility as tool for identifying joints that might benefit from 
surgical or other interventions. In this context the HAL potentially may offer a better 
tool in PWH with widespread joint disease for monitoring joint function, with a focus 
on functional and participation issues rather than on joint health per se.  
Further research is needed to establish to establish the validity and specificity of 
current HJHS scoring system for assessing severity of joint disease, and the relative 
value of HJHS and HAL in identification of patients for surgical intervention, and their 
correlation to other health measures such as health related quality of life and pain.  
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 In conclusion we have shown that comprehensive MSK assessment needs both a 
physical and functional assessment as neither can be used to categorise the severity of 
joint damage. Further, our data suggests that with widespread multi-joint 
involvement, the joint score alone is not useful in identifying potential issues. The use 
of the HJHS and HAL with those with mild to moderate joint disease would appear to 
offer clinical value, whilst the HAL independently may be more useful in those with 
widespread joint disease. As PWSH and multi-arthropathy continue to move into older 
age, we must ensure that services meet their needs. It is also imperative that 
assessments, both patient informed and clinician led, help ensure that subsequent 
interventions are evaluated by the most appropriate and useful outcome for the 
patient and healthcare professional.   
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Table 1- HJHS and HAL domain descriptions 
 
HJHS scoring domains 
(6 joints – Right/Left: elbow, knee, 
ankle) 
 
HAL domains 
42 multiple choice questions 
One month recall 
 Swelling (0-3) 
 
Duration of swelling (0-1) 
 
Muscle atrophy (0-2) 
 
Crepitus on motion (0-2) 
 
Flexion loss (0-3) 
 
Extension loss (0-3) 
 
Joint pain (0-2) 
 
Strength (0-4) 
 
Global gait score (0-4) 
 
 
LSKS – Lying/ Sitting/ Kneeling/ Standing (8 
items) 
 
LEGS- Function of the legs (9 items) 
 
ARMS- Function of the arms (4 items) 
 
TRANS - Use of transportation (3 items) 
 
SELFC - Self-care (5 items)  
 
HOUSEH - Household tasks (6 items) 
 
LEISPO - Leisure Activities and sports (7 items) 
 
 
Combined component scoring from above domains: 
 
UPPER – Combined upper limb domain specific 
 
LOWBAS – Basic lower limb function 
 
LOWCOM – Complex lower limb function 
 
Score of 0-20 per joint 
Plus global gait score (observed) 
 
Total available score = 124 
Score range = 0-100 
(for both grand total and per domain) 
 
(0= very poor function, 100 = no functional issue) 
 
 
 
 
  
Table 2 – Patient demographics 
Patient numbers N= 120 males 
Diagnosis  SHA = 96, SHB= 24 
Treatment regime Prophylaxis = 93   
On Demand = 27  
Age range 19-73 (median 33) 
Co-infection HCV = 14, HIV= 14, HCV & HIV= 6 
Inhibitor FVIII= 1, FIX = 2 
Orthopaedic surgery Total hip replacement - 4 
Total knee Replacement – 24 
Total ankle replacement – 2 
Radial head excision – 2 
Ankle debridement – 2 
Ankle arthrodesis - 6 
 
 
 
  
Table 3 – HJHS and HAL domain scores by age 
     Age 
Total cohort 
(N=120) 
18-30 
(N=50) 
31-50 
(N=47) 
51-73 
(N=23) 
SHA/SHB (N=120) 98/22 39/11 40/7 17/6 
  HJHS scores: Median (Range) 
Total HJHS 
 
19 (IQR 7-39) 
(0-114) 
7 (IQR 1-14) 
(0-63) 
25 (IQR 15-41) 
(4-64) 
44 (IQR 21-57) 
(14-114) 
Total Elbows (R&L) 4 (0-13) 0 (0-3) 7 (0-13) 14 (9-23) 
Total Knees (R&L) 2 (0-7) 0 (0-2) 2 (0-6) 10 (3-13) 
Total Ankles (R&L) 11 (0-19) 3 (0-8) 12 (6-12) 18 (10-23) 
Global Gait Scores 2 (0-4) 0 (0-1) 3 (1-4) 4 (3-4) 
  HAL Domains: Median (range)  
TOTAL HAL 
 
80 (13.3-100) 
(54.2-94.6) 
90.4 (46-100) 
(IQR 76.7-98.1) 
71.7 (13-100) 
(IQR 57-87.1) 
49.5 (13.3-95.2) 
(IQR 40.5-69.5) 
LSKS 75 (10-100) 
(IQR 52.5-92.5) 
88.8 (47.5-100) 
(IQR 75-100) 
70 (7.5-100) 
(IQR 52.5-85) 
37.5 (10-100) 
(IQR 30-67.5) 
LEGS 66.7 (8.9-100) 
(IQR 40-91.1) 
82.2 (28.9-100) 
(IQR 66.7-97.8) 
55.6 (0-100) 
(IQR 40-80) 
28.9 (8.9-91.1) 
(IQR 22.2-60) 
ARMS 85 (10-100) 
(IQR 55.5-100) 
100 (25-100) 
(IQR 85-100) 
80 (10-100) 
(IQR 55-100) 
65 (10-90) 
(IQR 45-80) 
TRANS 86.7 (10-100) 
(IQR 60-100) 
96.7 (20-96.7) 
(IQR 80-100) 
80 (13-100) 
(IQR 60-100) 
50 (10-100) 
(IQR 33.3-100) 
SELFC 96 (20-100) 
(IQR 72-100) 
100 (20-100)  
(IQR 92-100) 
92 (20-100) 
(IQR 68-100) 
72 (20-100) 
(IQR 64-100) 
HOUSEH 93.3 (13.3-100) 
(IQR 63.3-100) 
100 (46.7-100) 
(IQR 90-100) 
86.7 (10-100) 
(IQR 63.3-100) 
70 (13.3-100) 
(IQR 53.3-93.3) 
LEISPO 80 (2.9-100) 
(IQR 56-96) 
91.4 (40-100) 
(IQR 71.4-100) 
73.3 (10-100) 
(IQR 56.7-88.6) 
52 (2.9-100) 
(IQR 40-80) 
UPPER 88.9 (17.8-100) 
(IQR 66.7-100) 
97.8 (42.2-100) 
(IQR 88.9-100) 
84.4 (10-100) 
(IQR 62.7-95.6) 
68.9 (17.8-95.6) 
(IQR 55.6-88.9) 
LOWBAS 70 (6.7-100) 
(IQR 50-96.7) 
86.7 (30-100) 
(IQR 66.7-100) 
63.3 (6.7-100) 
(IQR 53.3-90) 
36.7 (6.7-100) 
(IQR 26.7-63.3) 
LOWCOM 62.2 (0-100) 
(IQR 37.5-86.7) 
80 (37.5-100) 
(IQR 60-97.8) 
55 (4.4-100) 
(IQR 40-80) 
20 (0-91.1) 
(IQR 15.6-48.9) 
(IQR =25th and 75th centile)  
Table 4 – Correlation values between HAL domain scores and HJHS domain scores 
 
   HJHS                                                           
 
WHOLE GROUP 
(N=120) 
Age: 18-30 
(N= 50) 
Age: 31-50 
(N=47) 
Age: 51-73 
(N=23) 
TOTAL 
SCORE 
TOTAL 
LL 
TOTAL 
UL 
 
TOTAL 
SCORE 
TOTAL 
LL 
TOTAL 
UL 
TOTAL 
SCORE 
TOTAL 
LL 
TOTAL 
UL 
TOTAL 
SCORE 
 
TOTAL 
LL 
TOTAL 
UL 
TOTAL SCORE -0.66     * 
 
  -0.59     *   -0.41     *   -0.41    **   
LSKS  
 
-0.64     *   -0.58    *   -0.25    **   -0.57     *  
LEGS  
 
-0.60     *   -0.61     *   -0.37    **   -0.4  
ARMS 
 
  -0.60     *   -0.32        -0.46      *   -0.44    ** 
TRANS 
 
-0.55     *   -0.43     *   -0.36     *   -0.53    **   
SELFC 
 
 -0.56    * -0.56     *  -0.31 -0.02  -0.25    ** -0.45    *  -0.55     * -0.36    ** 
HOUSEH 
 
-0.47   **   -0.43     *   -0.25   -0.26   
LEISPO 
 
-0.55     *   -0.5     *   -0.41     *   -0.22   
UPPER 
 
  -0.53     *   -0.38        -0.39     *   -0.43    ** 
LOWBAS 
 
 -0.58     *   -0.52     *   -0.32    **   -0.45  
LOWCOM 
 
 -0.66     *   -0.63     *   -0.4      *   -0.62    **  
* Key: *=p<0.01   **=p<0.05 
HJHS = Haemophilia Joint Health Score   HAL = Haemophilia Activities List   Total UL (upper limb) = right and left elbow scores  
Total LL (lower limb) = right and left knee and ankle scores LSKS: Lying down/sitting/kneeling/standing  LEGS: function of legs   ARMS: function of arms 
 TRANSP: Use of Transportation    SELFC: Self-care    HOUSEH: Household tasks  LEISPO: Leisure activities and sports 
 UPPER: Upper extremity activities    LOWBAS: Basic lower limb activities  LOWCOM: Complex lower extremity activities 
Figure 1: Scattergraph to show relationship between total HAL and total joint score 
(a) in all patients (b) grouped according to age (<30 years and 30+ years) (HAL and 
HJHS)  
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